Anaplastic Astrocytoma Pipeline Review, H2 2017 - 19 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H2 2017" report to their offering.

Anaplastic Astrocytoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Unknown stages are 4, 8, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.

Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Anaplastic Astrocytoma - Overview
  3. Anaplastic Astrocytoma - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Anaplastic Astrocytoma - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Anaplastic Astrocytoma - Companies Involved in Therapeutics Development
  • Advantagene Inc
  • Alfa Wassermann SpA
  • Amgen Inc
  • AngioChem Inc
  • Astellas Pharma Inc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Burzynski Research Institute Inc
  • Cavion LLC
  • Celldex Therapeutics Inc
  • Merrimack Pharmaceuticals Inc
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • Orbus Therapeutics Inc
  • Pfizer Inc
  • Tocagen Inc
  • Tragara Pharmaceuticals Inc
  • TVAX Biomedical Inc
  • ZIOPHARM Oncology Inc

For more information about this report visit https://www.researchandmarkets.com/research/4wphpg/anaplastic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Brain Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Brain Cancer Drugs